Evaluación ecológica en el deterioro cognitivo leve y enfermedad de Alzheimer mediante el Rivermead Behavioural Memory Test / Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test

Objetivos: El Rivermead Behaviou al Memory Test (RBMT) es una batería ecológica breve que permite predecir el funcionamiento mnésico del sujeto en la vida diaria. Evaluamos mediante el RBMT el funcionamiento mnésico en la vida diaria, de pacientes con deterioro cognitivo leve (DCL), enfermedad de Alzheimer (EA) y sujetos sanos, así como las diferencias entre perfiles mnésicos de los sujetos DCL estables al año y los que progresarán a EA. Pacientes y métodos: Muestra de 91 sujetos con 60 o más años, 30 controles, 27 DCL y 34 pacientes con EA. Se evalúa a los sujetos mediante MMSE y RBMT. Resultados: Cuarenta hombres y 51 mujeres, con edad y escolaridad media de 74,29 ± 6,71 y 5,87 ± 2,93 años, respectivamente. En las puntuaciones totales, perfil y global del RBMT (p < 0,001) y del MMSE (p < 0,05), los sujetos control puntúan significativamente más alto que los DCL y estos que los EA. En todos los subtest, los controles (p < 0,001) y DCL (p < 0,05) se diferencian de la EA. Subtest prospectivos, retrospectivos y de orientación diferencian al grupo control del DCL (p < 0,05). Los sujetos DCL que progresan a EA puntúan más bajo en la exploración inicial en las puntuaciones totales del RBMT, MMSE y en el recuerdo del nombre, objeto personal, recuerdo inmediato de la historia, recuerdo diferido del recorrido y orientación (p < 0,05), reconocimiento de dibujos, recuerdo diferido de la historia y del mensaje (p < 0,01). Conclusiones: RBMT es una prueba ecológica de memoria episódica útil para diferenciar entre sí sujetos controles/DCL/EA, que además permite detectar a los pacientes con DCL que progresan a EA

Introduction: The Rivermead Behavioural Memory Test (RBMT) is a short, ecologically-valid memory test battery that can provide data about a subject's memory function in daily life. We used RBMT to examine daily memory function in patients with mild cognitive impairment (MCI), Alzheimer disease (AD), and in healthy controls. We also evaluated differences between the memory profiles of subjects whose MCI remained stable after 1 year and those with conversion to AD. Patients and methods: Sample of 91 subjects older than 60 years: 30 controls, 27 MCI subjects and 34 AD patients. Subjects were assessed using MMSE and RBMT. Results: The 40 men and 51 women in the sample had a mean age of 74.29 ± 6.71 and 5.87 ± 2.93 years of education. For the total profile and screening RBMT scores (P < .001) and total MMSE scores (P < .05), control subjects scored significantly higher than those with MCI, who in turn scored higher than AD patients. In all subtests, the control group (P < .001) and MCI group (P<.05) were distinguishable from the AD group. Prospective, retrospective, and orientation subtests found differences between the MCI and control groups (P < .05). MCI subjects who progressed to AD scored lower at baseline on the total RBMT and MMSE, and on name recall, belongings, story - immediate recall, route - delayed recall, orientation (P < .05), face recognition, story - delayed recall, and messages - delayed recall sections (P < .01). Conclusions: RBMT is an ecologically-valid episodic memory test that can be used to differentiate between controls, MCI subjects, and AD subjects. It can also be used to detect patients with MCI who will experience progression to AD

Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test.

INTRODUCTION: The Rivermead Behavioural Memory Test (RBMT) is a short, ecologically-valid memory test battery that can provide data about a subject's memory function in daily life. We used RBMT to examine daily memory function in patients with mild cognitive impairment (MCI), Alzheimer disease (AD), and in healthy controls. We also evaluated differences between the memory profiles of subjects whose MCI remained stable after 1 year and those with conversion to AD. PATIENTS AND METHODS: Sample of 91 subjects older than 60 years: 30 controls, 27 MCI subjects and 34 AD patients. Subjects were assessed using MMSE and RBMT. RESULTS: The 40 men and 51 women in the sample had a mean age of 74.29±6.71 and 5.87±2.93 years of education. For the total profile and screening RBMT scores (P<.001) and total MMSE scores (P<.05), control subjects scored significantly higher than those with MCI, who in turn scored higher than AD patients. In all subtests, the control group (P<.001) and MCI group (P<.05) were distinguishable from the AD group. Prospective, retrospective, and orientation subtests found differences between the MCI and control groups (P<.05). MCI subjects who progressed to AD scored lower at baseline on the total RBMT and MMSE, and on name recall, belongings, story-immediate recall, route-delayed recall, orientation (P<.05), face recognition, story-delayed recall, and messages-delayed recall sections (P<.01). CONCLUSIONS: RBMT is an ecologically-valid episodic memory test that can be used to differentiate between controls, MCI subjects, and AD subjects. It can also be used to detect patients with MCI who will experience progression to AD.